RiverPark Advisors LLC Sells 5,186 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC)

RiverPark Advisors LLC lowered its stake in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 27.5% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 13,642 shares of the medical technology company’s stock after selling 5,186 shares during the period. RiverPark Advisors LLC’s holdings in Alphatec were worth $76,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Van ECK Associates Corp lifted its stake in Alphatec by 11.8% in the second quarter. Van ECK Associates Corp now owns 12,275 shares of the medical technology company’s stock valued at $128,000 after buying an additional 1,300 shares in the last quarter. ProShare Advisors LLC lifted its position in shares of Alphatec by 8.5% in the first quarter. ProShare Advisors LLC now owns 16,572 shares of the medical technology company’s stock worth $229,000 after purchasing an additional 1,304 shares in the last quarter. Bayesian Capital Management LP lifted its position in shares of Alphatec by 5.6% in the first quarter. Bayesian Capital Management LP now owns 27,000 shares of the medical technology company’s stock worth $372,000 after purchasing an additional 1,442 shares in the last quarter. Atria Investments Inc lifted its position in shares of Alphatec by 8.0% in the third quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company’s stock worth $109,000 after purchasing an additional 1,460 shares in the last quarter. Finally, Cetera Advisors LLC lifted its position in shares of Alphatec by 15.6% in the first quarter. Cetera Advisors LLC now owns 12,720 shares of the medical technology company’s stock worth $175,000 after purchasing an additional 1,720 shares in the last quarter. Institutional investors own 66.35% of the company’s stock.

Alphatec Stock Performance

NASDAQ:ATEC opened at $8.23 on Friday. The company has a 50 day simple moving average of $6.30 and a two-hundred day simple moving average of $8.36. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. Alphatec Holdings, Inc. has a fifty-two week low of $4.88 and a fifty-two week high of $17.34.

Analyst Ratings Changes

Several analysts have issued reports on ATEC shares. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Alphatec in a research report on Thursday, October 31st. Canaccord Genuity Group reaffirmed a “buy” rating and set a $20.00 price target on shares of Alphatec in a research report on Friday, August 30th. Wells Fargo & Company decreased their price objective on shares of Alphatec from $26.00 to $19.00 and set an “overweight” rating on the stock in a report on Thursday, August 1st. Needham & Company LLC restated a “buy” rating and issued a $13.00 price target on shares of Alphatec in a research note on Thursday, October 31st. Finally, Lake Street Capital decreased their price target on shares of Alphatec from $32.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, September 3rd. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $17.00.

Insider Buying and Selling at Alphatec

In other Alphatec news, Director David M. Demski purchased 50,000 shares of the firm’s stock in a transaction on Wednesday, August 21st. The stock was acquired at an average price of $5.67 per share, for a total transaction of $283,500.00. Following the purchase, the director now owns 288,441 shares of the company’s stock, valued at $1,635,460.47. This trade represents a 20.97 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 22.80% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.